Justin A Ezekowitz
Overview
Explore the profile of Justin A Ezekowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
354
Citations
9136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Coats A, Anker S, Lund L, Filippatos G, Rossignol P, Pitt B, et al.
JACC Heart Fail
. 2024 Sep;
12(12):2026-2037.
PMID: 39340493
Background: For heart failure with reduced ejection fraction (HFrEF), suboptimal use of renin-angiotensin-aldosterone system inhibitors (RAASis), including mineralocorticoid receptor antagonists (MRAs), due to hyperkalemia, may be improved by potassium binders....
12.
Pitt B, Anker S, Lund L, Coats A, Filippatos G, Rossignol P, et al.
J Am Coll Cardiol
. 2024 Sep;
84(14):1295-1308.
PMID: 39322323
Background: Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF). Objectives: This study sought to...
13.
Westerhout C, Rathwell S, Anstrom K, Hernandez A, Ponikowski P, Ezekowitz J, et al.
J Card Fail
. 2024 Aug;
31(3):551-558.
PMID: 39182825
Background: In VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), participants with heart failure (HF) and reduced ejection fraction, vericiguat decreased the primary composite outcome...
14.
Weir M, Rossignol P, Pitt B, Lund L, Coats A, Filippatos G, et al.
Am J Nephrol
. 2024 Aug;
55(6):672-689.
PMID: 39159624
Introduction: Renin-angiotensin-aldosterone system inhibitor (RAASi; including mineralocorticoid receptor antagonists [MRAs]) benefits are greatest in patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD); however, the...
15.
Paterson D, White J, Beaulieu C, Sherrington R, Prado C, Tandon P, et al.
Front Med (Lausanne)
. 2024 Aug;
11:1392169.
PMID: 39114821
Introduction: Short-term clinical outcomes from SARS-CoV-2 infection are generally favorable. However, 15-20% of patients report persistent symptoms of at least 12 weeks duration, often referred to as long COVID. Population...
16.
Grubic N, Ezekowitz J
Can J Cardiol
. 2024 Jul;
40(11):2180-2184.
PMID: 39069071
No abstract available.
17.
Lopez J, Liu Y, Butler J, Del Prato S, Ezekowitz J, Lam C, et al.
J Am Coll Cardiol
. 2024 Jul;
84(3):233-243.
PMID: 38986667
Background: Diabetic cardiomyopathy (DbCM) increases risk of overt heart failure in individuals with diabetes mellitus. Racial and ethnic differences in DbCM remain unexplored. Objectives: The authors sought to identify racial...
18.
Saldarriaga C, Colin-Ramirez E, Islam S, Alemayehu W, Macdonald P, Ross H, et al.
J Card Fail
. 2024 Jul;
30(9):1073-1082.
PMID: 38971298
Objectives: This post hoc analysis of SODIUM-HF (Study of Dietary Intervention under 100 mmol in Heart Failure) assessed the association between baseline dietary sodium intake and change at 6 months...
19.
Verma S, Butler J, Borlaug B, Davies M, Kitzman D, Shah S, et al.
J Am Coll Cardiol
. 2024 Jun;
84(9):773-785.
PMID: 38913003
Background: More women than men have heart failure with preserved ejection fraction (HFpEF). Objectives: The purpose of this study was to assess baseline characteristics and treatment effect of semaglutide by...
20.
Nouhravesh N, Garg J, Rockhold F, DE Pasquale C, OMeara E, Lewis G, et al.
Eur J Heart Fail
. 2024 Jun;
PMID: 38896006
Aims: Ferric carboxymaltose (FCM) is guideline-recommended for iron deficiency (ID) in heart failure with reduced ejection fraction (HFrEF). Despite a well-established safety profile, the magnitude and clinical significance of FCM-induced...